Complement inhibitors protect the neuromuscular junction from IgG1/IgG3-mediated complement injury and therefore demonstrate their greatest efficacy in AChR- and LRP4-positive MG, where classical pathway activation is central. This evidence concerns the gene IGHG3 and myasthenia gravis.